Table 1 Demographics of 206 patients with the bladder cancer
From: Serum lactate dehydrogenase level predicts the prognosis in bladder cancer patients
Variables | Total patients (n = 206) | Groups | P | |
|---|---|---|---|---|
Low LDH | High LDH | |||
< 225 U/L | ≥ 225 U/L | |||
Median age (years) | 57 | 0.073 | ||
< 64 | 93 (45.1%) | 73 (49.0%) | 20 (35.1%) | |
≥ 64 | 113 (54.9%) | 76 (51.0%) | 37 (64.9%) | |
Sex, n% | 0.709 | |||
Male | 159 (77.2%) | 114 (76.5%) | 45 (78.9%) | |
Female | 47 (22.8%) | 35 (23.5%) | 12 (21.1%) | |
Smoking | 0.592 | |||
Yes | 95 (46.1%) | 67 (45.0%) | 28 (49.1%) | |
No | 111 (53.9%) | 82 (55.0%) | 29 (50.9%) | |
Pathological type | < 0.001 | |||
Transitional cell carcinoma | 188 (91.3%) | 144 (96.6%) | 44 (77.2%) | |
Squamous cell carcinoma | 12 (5.8%) | 4 (2.7%) | 8 (14.0%) | |
Adenocarcinoma | 6 (2.9%) | 1 (0.7%) | 5 (8.8%) | |
T stage | < 0.001 | |||
Ta, Tis, T1 | 122 (59.2%) | 101 (67.8%) | 21 (36.8%) | |
T2–3 | 84 (40.8%) | 48 (32.2%) | 36 (63.2%) | |
N stage | < 0.001 | |||
N0 | 183 (88.8%) | 144 (96.6%) | 39 (68.4%) | |
N1–3 | 23 (11.2%) | 5 (3.4%) | 18 (31.6%) | |
M stage | < 0.001 | |||
M0 | 188 (91.3%) | 146 (98.0%) | 42 (73.7%) | |
M1 | 18 (8.7%) | 3 (2.0%) | 15 (26.3%) | |
Tumor size (cm) | 0.011 | |||
< 3 cm | 55 (26.7%) | 47 (31.5%) | 8 (14.0%) | |
> 3 cm | 151 (73.3%) | 102 (68.5%) | 49 (86.0%) | |
LVI | < 0.001 | |||
Present | 76 (36.9%) | 43 (28.9%) | 33 (57.9%) | |
Absent | 130 (63.1%) | 106 (71.1%) | 24 (42.1%) | |
PNI | 0.075 | |||
Present | 29 (14.1%) | 17 (11.4%) | 12 (21.1%) | |
Absent | 177 (85.9%) | 132 (88.6%) | 45 (78.9%) | |
Multifocality | 0.559 | |||
Unifocal | 161 (78.2%) | 118 (79.2%) | 43 (75.4%) | |
Multifocal | 45 (21.8%) | 31 (20.8%) | 14 (24.6%) | |